First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well
it works in imaging patients with primary or cancer that has spread to the breast,
colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may
improve the ability to locate cancer in the body.
Phase:
Early Phase 1
Details
Lead Sponsor:
Julie L. Sutcliffe, Ph.D University of California, Davis